The clinical pharmacology of alkylating agents in high-dose chemotherapy

Anti-Cancer Drugs

Volumn 11, Issue 7, 2000, Pages 515-533

  Huitema, Alwin D R ^a,b   Smits, Karen Doesburg ^a   Mathôt, Ron A A ^a   Schellens, Jan H M ^b,c   Rodenhuis, Sjoerd ^b   Beijnen, Jos H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alkylating agents; Clinical pharmacology; High dose chemotherapy

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; IFOSFAMIDE; MELPHALAN; THIOTEPA;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW;

ALKANESULFONATES; ANTINEOPLASTIC AGENTS, ALKYLATING; AZIRIDINES; HUMANS; NITROGEN MUSTARD COMPOUNDS; NITROSOUREA COMPOUNDS; ORGANOPLATINUM COMPOUNDS; TRIAZENES;

EID: 0033800062     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200008000-00002     Document Type: Review

References (208)

1. High-dose chemotherapy for solid tumors
2. Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism
3. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism
4. Clinical pharmacokinetics of cyclophosphamide
5. Clinical pharmacokinetics of cyclophosphamide
6. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
7. Pharmacokinetics of alkylating agents
8. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
9. Rapid development of enhanced clearance after high-dose cyclophosphamide
10. Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients
11. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation
12. Population-pharmacokinetics (PK) study of high-dose cyclophosphamide (CPP) in a program of high dose chemotherapy (HDCT) and peripheral blood stem cell (PBSC) transplantation in high risk (HR) breast cancer (BC) patients (PTS)
13. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
14. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: Exposure to activated metabolites
15. Ifosfamide metabolism and pharmacokinetics
16. Ifosfamide clinical pharmacokinetics
17. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites
18. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: Correlation of plasma drug levels with renal toxicity
19. Renal clearance and protein binding of melphalan in patients with cancer
20. High-dose melphalan dosage adjustment: Possibility of using a test-dose
21. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies
22. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation
23. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study
24. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: Pharmaco-kinetics and toxicity
25. Pharmacokinetics of high-dose melphalan in adults: Influence of renal function
26. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support
27. Pharmacokinetics of high-dose melphalan in children and adults
28. Pharmacokinetics of high dose melphalan
29. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases
30. Phase I/pharmacokinetic reevaluation of thioTEPA
31. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: Evidence for dose-dependent plasma clearance of thiotepa
32. Pharmacokinetics of thio-TEPA at two different doses
33. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects
34. High-dose iv thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer
35. Pharmacokinetics of continuous-infusion high-dose thiotepa
36. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation
37. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide
38. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies
39. Pharmacokinetic study of high-dose thioTEPA (T) and mitoxantrone (M) with autologous stem cell support (PBSCT) in the treatment of high risk breast cancer
40. Dosing of thioTEPA for myeloablative therapy
41. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in high-dose chemotherapy
42. Busulfan kinetics
43. Pharmacokinetic and metabolic studies of high-dose busulphan in adults
44. The impact of obesity and disease on busulfan oral clearance in adults
45. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
46. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
47. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics
48. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
49. Pharmacokinetics of BCNU in man: A preliminary study of 20 patients
50. Pharmacokinetics and immediate effects of high-dose carmustine in man
51. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: Pharmacodynamic evaluation of carmustine
52. High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma
53. Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimi-dazole-4-carboxamide (AIC) following different dose schedules
54. Clinical pharmacokinetics of high-dose DTIC
55. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients
56. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors
57. Clinical pharmacokinetics of carboplatin
58. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
59. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
60. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer
61. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
62. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h
63. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program
64. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
65. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients
66. Pharmacokinetics of cisplatin and its monohydrated complex in humans
67. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics
68. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B518-Asta) in experimental turnouts in rats
69. Metabolism and pharmacokinetics of cyclophosphamide and related oxazaphosphorines
70. 359 allele as low-K(m) catalysts of cyclophosphamide and ifosfamide activation
71. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes
72. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
73. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
74. Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide
75. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferase
76. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans
77. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent
78. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor
79. Hemorraghic cystitis complicating bone marrow transplantation
80. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
81. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response
82. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosurea
83. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxy-cyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
84. Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy
85. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors
86. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients
87. Urinary excretion of cyclophosphamide in humans, determined by phosphorous-31 nuclear magnetic resonance spectroscopy
88. The effect of cimetidine on cyclophosphamide metabolism in rabbits
89. Reduction of cyclophosphamide bioactivation by thioTEPA: Critical sequence-dependency in high-dose chemotherapy regimens
90. Phenobarbital effects on cyclophosphamide pharmacokinetics in man
91. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer
92. The effect of fluconazole on cyclophosphamide metabolism in children
93. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites
94. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis
95. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease
96. Correlation of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics to response and toxicity in patients with primary breast cancer
97. Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide
98. Chloroacetaldehyde - Antitumor activity in vivo and mode of action of the ifosfamide metabolite
99. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy
100. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
101. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients
102. Cytotoxic alpha amino acids and endopeptides
103. High-dose intravenous melphalan: A review
104. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion
105. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity
106. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma
107. Stability of melphalan solutions during preparation and storage
108. In vitro degradation of L-phenylalanine mustard (L-PAM)
109. High dose melphalan in children with advanced malignant disease. A pharmacokinetic study
110. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer
111. Pharmacokinetically guided dosing for intravenous melphalan: A pilot study in patients with advanced ovarian adenocarcinoma
112. Pharmacokinetics of very high-dose oral melphalan in cancer patients
113. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion
114. The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil
115. Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil
116. The pharmacokinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen
117. Oral melphalan kinetics
118. Interaction of cimetidine with oral melphalan: A pharmacokinetic study
119. Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity
120. Metabolism and reactions of alkylating agents
121. Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA
122. Chemistry, pharmacology and pharmacokinetics of thioTEPA: A review
123. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites
124. Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian cancer
125. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients
126. The comparative physiological disposition of thioTEPA and TEPA in the dog
127. 32P labelled triethylenethiophosphoramide
128. Biotransformation of N,N',N''-triethylenethiophosphoramide: Oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P450 monooxygenase
129. N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents
130. A search for new metabolites of N,N',N''-triethylenethiophosphoramide
131. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide
132. The binding of thio-TEPA in human serum and to isolated serum protein fractions
133. High-dose thiotepa alone and in combination regimens with bone marrow support
134. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
135. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation
136. Busulfan bioavailability
137. Chronopharmacology of high-dose busulfan in children
138. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan
139. Pharmacokinetics of high-dose busulfan in children
140. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study
141. Association of busulfan area under the curve with veno-occlusive disease following BMT
142. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation
143. Busulfan disposition in children
144. Optimization of busulphan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
145. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
146. Pharmacokinetics of oral busulfan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation
147. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
148. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation
149. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
150. An improved limited sampling model for individualised busulphan dosing in bone marrow transplantation in children
151. Busulfan test dose area under the curve (AUC) predicts dose required to achieve targeted therapeutic concentration in bone marrow transplant (BMT) patients
152. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: Rationale and pitfalls
153. Mechanism of action of the nitrosoureas - IV. Synthesis of the 2-haloethylnitrosourea-induced DNA cross-link 1-(3-cytosinyl),2-(1-guanyl)ethane
154. DNA cross-linking and monoadduct repair in nitrosoureatreated human tumour cells
155. 6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl (methylsulfonyl)methanesulfonate
156. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study
157. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine
158. Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography
159. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes
160. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC 4366650 and cryopreserved autologous marrow transplantation for refractory cancer: A phase I-II study
161. High-dose combination alkylating agents with autologous bone marrow support: A phase I trial
162. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies
163. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood
164. Mechanism of hydrolysis of halogenated nitrosoureas
165. The effect of phenobarbital pretreatment on the antitumor activity- of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo)-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU
166. Microsomal metabolism of nitrosoureas
167. Involvement of FMN and phenobarbital cytochrome P450 in stimulating a one-electron reductive denitrosation of 1-(2-chloroethyl)-3-cy-clohexyl-1-nitrosourea catalyzed by NADPH-cytochrome P450 reductase
168. Denitrosation of 1,3-bis(2-chloro-ethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells
169. Glutathione-dependent denitrosation of N,N'-bis(2-chloroethyl)N-nitrosourea (BCNU): Nitrite release catalyzed by mouse liver cytosol in vitro
170. Metabolism of the chloroethylnitrosoureas
171. Cyclophosphamide, cisplatin, and carmustine: Pharmacokinetics of carmustine following multiple alkylating-agent interactions
172. Metabolic activation of dacarbazine by human cytochrome P450: The role of CYP1A1, CYP1A2, and CYP2E1
173. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
174. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide
175. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid maligo nancies
176. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
177. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
178. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer
179. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma
180. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma
181. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
182. Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarbocylato)platinum(II) differ only in the kinetics of their interaction with DNA
183. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: A case report and pharmacokinetic study
184. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function
185. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
186. Renal handling of carboplatin
187. Application of the area under the curve of carboplatin in predicting toxicity and efficacy
188. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA levels
189. Prediction of creatinine clearance from serum creatinine
190. Accurate prediction of renal function for carboplatin dosing
191. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
192. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients
193. Evaluation of formulas using the serum creatinine level to calculate the optimal dosing of carboplatin
194. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: A comparison of the performance of three formulae
195. Carboplatin dosage formulae can generate inaccurate predictions of carboplatin exposure in carboplatin/paclitaxel combination regimens
196. Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods
197. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing
198. Evaluation of two dose individualisation methods for carboplatin
199. A sequential Bayesian algorithm for dose individualisation of carboplatin
200. Limited-sampling models for estimation of the carboplatin area under the curve
201. A limited sampling method for estimation of the carboplatin area under the curve
202. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model
203. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve
204. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination
205. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen
206. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
207. Evolution of high-dose cisplatin
208. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial